Leukeran (Chlorambucil)

Chlorambucil belongs to the alkylating agent class. It forms covalent bonds with DNA, creating cross‑links that prevent DNA replication and transcription. This disruption leads to apoptosis of rapidly dividing cancer cells, particularly those of lymphoid origin, thereby reducing tumor growth.

The specific dose of Leukeran is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, and overall health. Dosage regimens are individualized and should follow the prescriber’s instructions and local treatment guidelines.

Chlorambucil is classified as potentially harmful to a developing fetus and may be excreted in breast milk. Its safety in pregnancy or lactation has not been established, so it is generally avoided. Women of childbearing potential should use effective contraception during treatment and for a period thereafter as advised by their physician.

To request Leukeran, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leukeran (chlorambucil) is an oral alkylating agent, offering convenience compared with intravenous regimens. It is generally less intensive than some newer targeted therapies but remains effective for many lymphoid cancers. Choice of therapy depends on disease characteristics, patient tolerance, and physician assessment of benefit‑risk balance.

Leukeran tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain stability throughout the shelf life.

Leukeran is taken orally as a tablet, usually with water. The prescribing physician will specify the dosing schedule, which may involve daily or intermittent administration. Patients should follow the exact timing and any food‑related instructions provided by their healthcare professional.

The most serious risks include severe bone marrow suppression leading to pancytopenia, life‑threatening infections, secondary malignancies such as acute leukemia, hepatic toxicity, and rare pulmonary complications. Patients should be monitored closely for signs of infection, bleeding, or organ dysfunction.

Leukeran is contraindicated in individuals with known hypersensitivity to chlorambucil or other alkylating agents, patients with severe bone marrow failure, active uncontrolled infections, and pregnant or nursing women unless the benefits outweigh the risks. A thorough medical evaluation is required before initiating therapy.